One To Watch
Fosun Pharma
Company Overview
A Shanghai-headquartered pharmaceutical group operating across innovative medicines, medical devices, and diagnostics, with a growing global pipeline spanning oncology, immunology, and neuroscience. Fosun Pharma is a subsidiary of Fosun International and is listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange. The group pursues a dual strategy of in-licensing international assets for the Chinese market while advancing its own R&D pipeline globally through out-licensing deals. Its business units include an Innovative Medicines Division, a MedTech Division, and a diagnostics segment.
Headquarters and Global Presence
Fosun Pharma is headquartered in Shanghai, China, with a commercial and R&D presence extending into the United States through Fosun Pharma USA Inc. The company has pursued acquisitions and licensing agreements across Europe, the Middle East, and North America to build an international commercial footprint.
Founding and History
Fosun Pharma was established in Shanghai and has grown through decades of acquisitions and partnerships to become one of China's top drugmakers. A landmark moment came with the formation of a joint venture with Kite Pharma, bringing CAR-T cell therapy to China. In September 2024, Fosun acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 million, securing full ownership of the CAR-T platform. In March 2025, the company divested its stake in private hospital operator United Family Healthcare for $124 million, signaling a sharper focus on its core pharmaceutical and biotech assets.
Therapy Areas and Focus
Fosun Pharma's pipeline is concentrated in oncology, immunology, and inflammation, with an expanding neuroscience interest following a 2026 collaboration with UAE-based Arcera Life Sciences. In immunology, the company has made targeted moves into autoimmune diseases through both in-licensed and proprietary small molecules. The group's oncology focus is anchored by its CAR-T infrastructure and a portfolio of precision medicines being advanced under the Innovative Medicines Division. Neuroscience is an emerging pillar, with the Arcera partnership covering licensing, technology development, and research.
Technology Platforms and Modalities
Fosun Kite, now fully owned by Fosun Pharma, commercializes axicabtagene ciloleucel, a CD19-directed CAR-T cell therapy, in mainland China — a product based on Gilead-owned Kite Pharma's Yescarta platform. In small molecules, the company has developed a DPP-1 inhibitor (XH-S004) and a selective TYK2/JAK1 inhibitor (AC-201) targeting inflammatory pathways. The group's R&D model blends internal discovery with active business development, using out-licensing of proprietary assets to validate their global value while retaining Chinese rights.
Key Pipeline and Programs
AC-201 is a highly selective TYK2/JAK1 inhibitor in-licensed from Accro Bioscience in August 2025, with Fosun holding exclusive rights to develop, manufacture, and commercialize it in Greater China, including the mainland, Hong Kong SAR, and Macau SAR. TYK2 inhibition has become a validated mechanism following the approval of deucravacitinib, and AC-201 is being positioned in autoimmune indications. XH-S004 is an orally administered DPP-1 inhibitor independently developed by Fosun Pharma and out-licensed to Expedition Therapeutics in August 2025 for all territories outside Greater China in a deal worth up to $645 million; DPP-1 inhibition is a clinically active approach in neutrophil-driven inflammatory diseases. FXS6837 is a proprietary asset out-licensed in August 2025 to Sitala, a UK-based biotech focused on inflammation and autoimmune diseases, underscoring Fosun's strategy of monetizing its pipeline internationally while retaining home-market control.
Recent Developments
In August 2025, Fosun executed three significant pipeline transactions in rapid succession: acquiring AC-201 rights for Greater China, out-licensing FXS6837 to Sitala, and executing the $645 million XH-S004 deal with Expedition Therapeutics. In April 2026, Fosun signed a strategic memorandum of understanding with Arcera Life Sciences of Abu Dhabi, covering neuroscience research, licensing, and technology development. In March 2025, the group completed the sale of its United Family Healthcare hospital stake to a Warburg Pincus-owned vehicle for $124 million, consolidating its pharmaceutical focus. Full ownership of Fosun Kite was secured in September 2024 for $27 million, giving the group unencumbered control of its China CAR-T commercial infrastructure.
Key Personnel
Wu Yifang serves as Executive Director, Chief Executive Officer, and President of Fosun Pharma, as well as Co-Chairman of the Innovative Medicines Division and Chairman and CEO of the Fosun MedTech Division, combining strategic oversight across the group's core business units. Xingli Wang serves as Co-President of Fosun Pharma and CEO of the Innovative Medicines Division, and has been a public face of the company's international partnership strategy, including the 2026 Arcera collaboration. Fosun Pharma USA Inc. is led by a dedicated leadership team with backgrounds from leading US and European pharmaceutical companies, spanning commercial operations and research and development.
Strategic Partnerships
Fosun Pharma's partnership strategy operates on two tracks: in-licensing international assets for the Chinese market, and out-licensing proprietary molecules globally. The $645 million XH-S004 deal with Expedition Therapeutics and the Sitala agreement for FXS6837, both signed in August 2025, demonstrate the global appetite for the company's pipeline. The April 2026 MOU with Arcera Life Sciences extends Fosun's reach into the Middle East across neuroscience and broader therapeutic licensing. Earlier arrangements include a deal with Helsinn Group for CINV assets in mainland China and a licensing agreement with Ardelyx for tenapanor in IBS-C and hyperphosphatemia.
FAQ Section
Fosun Pharma operates a two-track model: it in-licenses validated international assets such as the Ardelyx tenapanor and Helsinn CINV products for commercialization in China, while simultaneously out-licensing its own proprietary molecules to Western partners for development outside Greater China. The $645 million XH-S004 deal with Expedition Therapeutics and the Sitala agreement for FXS6837 illustrate how this approach generates upfront capital and validation for internal R&D while retaining lucrative home-market rights.
TYK2 inhibition was clinically validated by the approval of Bristol Myers Squibb's deucravacitinib for plaque psoriasis, establishing the pathway as a high-value target in autoimmune disease. AC-201, in-licensed from Accro Bioscience in August 2025, is described as a highly selective TYK2/JAK1 inhibitor, giving Fosun a next-generation entrant in a competitive but proven therapeutic space. Securing Greater China rights positions Fosun to address a large and underserved autoimmune patient population domestically.
Fosun stands out through its willingness to pursue both directions of technology transfer simultaneously — importing assets into China and exporting proprietary drugs outward — rather than relying solely on China-to-global licensing. Full ownership of Fosun Kite gives it a vertically integrated CAR-T infrastructure in China that few domestic peers can match. The April 2026 Arcera collaboration also signals an emerging Middle East strategy, diversifying beyond the traditional US and European expansion routes most Chinese pharma companies favor.
XH-S004 is an orally administered DPP-1 inhibitor independently developed by Fosun Pharma and out-licensed to Expedition Therapeutics in August 2025. DPP-1, also known as cathepsin C, activates neutrophil serine proteases implicated in a range of inflammatory diseases, and oral inhibitors of this target are an area of active clinical development. The deal's potential value of $645 million for ex-Greater China rights reflects strong commercial interest in the class, validated in part by AstraZeneca's brensocatib program.
Fosun Pharma's internal pipeline is concentrated in immunology and inflammation, oncology, and an emerging neuroscience axis. In inflammation, the company has produced at least two out-licensable assets — XH-S004 (DPP-1) and FXS6837 — with autoimmune applications, while AC-201 (TYK2/JAK1) broadens its immunology reach through in-licensing. Oncology is anchored by the CAR-T franchise through Fosun Kite, and neuroscience is being developed collaboratively through the Arcera MOU signed in April 2026.
Fosun Pharma is a large, revenue-generating commercial entity rather than a pre-revenue biotech, with listed status in Hong Kong and Shanghai. Its pipeline contains assets at various stages, with key near-term milestones tied to the clinical progression of AC-201, the advancement of XH-S004 by Expedition Therapeutics, and any regulatory developments for axicabtagene ciloleucel in China under the Fosun Kite umbrella. The group's active business development pace in 2025 and 2026 suggests further partnership announcements are likely near-term catalysts.
Fosun Pharma sits at an interesting inflection point, with several moving parts that could define its trajectory over the next 12-24 months:
Latest Fosun Pharma News
Today's issue
| Headless Content Management with Blaze